Recent News for VRCA - Verrica Pharmaceuticals Inc.

Date Title
Apr 6 Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
Apr 3 Last Week's Notable Insider Buys: PennyMac Financial, Republic Services And More
Apr 1 2 “Strong Buy” Stocks Insiders Are Snapping Up
Mar 29 Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
Mar 23 The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO
Mar 23 Verrica Announces Pricing of Public Offering of Common Stock
Mar 22 Verrica readies stock offering
Mar 22 Verrica Announces Proposed Public Offering of Common Stock
Mar 17 Verrica Pharma shares rise 6% on licensing deal for VP-102 in Japan
Mar 17 Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
Mar 12 The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs
Mar 4 Verrica Pharmaceuticals reports Q4 results
Mar 4 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
Mar 3 Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
Feb 23 Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
Feb 18 Vectoring Back In On Verrica Pharmaceuticals
Feb 17 FDA accepts Verrica's VP-102 NDA resubmission for review
Feb 17 Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Feb 11 The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Jan 19 Verrica's stock surges on positive data from late-stage VP-102 trials
Jan 19 Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference
Dec 24 Verrica Pharma perks up after H.C. Wainwright raised price target
Dec 24 Biggest Price Target Changes For Thursday
Dec 23 Verrica Pharma refiles US application for lead candidate in infectious skin disease
Dec 23 Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Back to the Main VRCA Page...